This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year

Summit Therapeutics (NASDAQ: SMMT) has been one of the hottest stocks to own over the past 12 months, with its valuation soaring 300% during that stretch. But things have slowed of late and since the start of 2025, the stock's returns have been flat. Investors are, after all, paying a hefty premium for a business which still isn't generating any consistent revenue; its market capitalization remains north of $13 billion.Hype and excitement around the potential for Summit's cancer treatment candidate, ivonescimab, has fueled the stock's rally. And while it might seem expensive and investors may be worried that it has peaked in value, there could be a catalyst on the horizon that may send the stock price even higher this year.The big reason investors have been paying a premium for Summit's stock is the potential for ivonescimab to be a massive game changer for the company. Last year, it outperformed Merck's top-selling cancer treatment, Keytruda, in a late-stage trial for non-small cell lung cancer. Even if ivonescimab were simply as good as Keytruda, that alone could make it a blockbuster and generate tens of billions of dollars in revenue for Summit. And if it's better, then its potential would be far greater.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool